Free tool
FAERS Monitor: Fasenra
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761070 or its brand name (Fasenra, Benralizumab). Reports on generic versions are filed under their own applications.
Reports
4,171
Serious
2,690
64% of reports
Hospitalization
1,016
Death reported
410
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- asthma613
- dyspnoea434
- death349
- drug ineffective295
- cough237
- pneumonia233
- headache224
- product dose omission issue217
- wheezing164
- fatigue136
- arthralgia133
- inappropriate schedule of product administration126
- malaise118
- pyrexia115
- pruritus108
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 175 |
| 2019 | 342 |
| 2020 | 341 |
| 2021 | 421 |
| 2022 | 367 |
| 2023 | 459 |
| 2024 | 694 |
| 2025 | 723 |
| 2026 | 647 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,988 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| asthmaSignal | 613 | 27.5 | 25.6 | 15,624 |
| wheezingSignal | 164 | 14.0 | 12.0 | 1,964 |
| coughSignal | 237 | 4.3 | 3.8 | 596 |
| dyspnoeaSignal | 434 | 3.9 | 3.5 | 945 |
| product dose omission issueSignal | 217 | 3.7 | 3.3 | 435 |
| pneumoniaSignal | 233 | 3.6 | 3.2 | 448 |
| inappropriate schedule of product administrationSignal | 126 | 3.5 | 3.0 | 227 |
| deathSignal | 349 | 2.0 | 1.8 | 193 |
| headache | 224 | 1.8 | 1.6 | 82 |
| pyrexia | 115 | 1.7 | 1.4 | 31 |
| arthralgia | 133 | 1.6 | 1.4 | 31 |
| pruritus | 108 | 1.4 | 1.2 | 13 |
| malaise | 118 | 1.4 | 1.1 | 11 |
| drug ineffective | 295 | 1.1 | 1.0 | 4 |
| fatigue | 136 | 0.9 | 0.7 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.